Compare Brunswick Corporation (BC) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Boston Scientific Corporation — how do they compare? Brunswick Corporation trades at $79.92 (market cap $5.28B), while Boston Scientific Corporation trades at $51.48 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 14.1× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.16% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BC | BSX | |
|---|---|---|
Market Cap | $5.28B | $74.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $108.14 |
52-Week Low | $58.75 | $42.63 |
Enterprise Value | $7.28B | $86.27B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brunswick Corporation (BC) trades at $79.54, down 1.11% on the day, with strong analyst support showing 22 buy ratings and a consensus price target of $85.33. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company posted a net loss of $137.3 million in 2025. Technical indicators show a bullish trend with support at $80 and resistance at $82, while fundamentals reveal mixed profitability with negative margins but positive cash flow from operations of $562.1 million.
The outlook remains cautiously optimistic given strong institutional backing and recent earnings beats, though investors face risks from negative profit margins and elevated P/E ratio of 73.92. The stock offers potential upside to analyst targets but requires monitoring of profitability improvements and debt management amid competitive pressures in the marine industry.
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
